Estabrook Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Estabrook Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12	Closed	-$488	–	402
2022 Q4	$488	Hold	12	–	–	﹤0.01%	411
2022 Q3	$784	Hold	12	–	–	﹤0.01%	399
2022 Q2	$729	Hold	12	–	–	﹤0.01%	409
2022 Q1	$753	Hold	12	–	–	﹤0.01%	405
2021 Q4	$909	Hold	12	–	–	﹤0.01%	430
2021 Q3	$1.34K	Hold	12	–	–	﹤0.01%	305
2021 Q2	$1.94K	Hold	12	–	–	﹤0.01%	300
2021 Q1	$1.46K	Hold	12	–	–	﹤0.01%	307
2020 Q4	$1.84K	Hold	12	–	–	﹤0.01%	310
2020 Q3	$1K	Hold	12	–	–	﹤0.01%	303
2020 Q2	$882	Hold	12	–	–	﹤0.01%	316
2020 Q1	$509	Hold	12	–	–	﹤0.01%	321
2019 Q4	$731	Buy	+12	New	+$655	﹤0.01%	327

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Estabrook Capital Management's CRSP Position: Q1 2023 in Review

Estabrook Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2023, closing a stake of 12 shares — an estimated $488 sold.

Estabrook Capital Management first reported a position in CRSP in Q4 2019 and held it in 13 quarters. The position peaked at $1.94K in Q2 2021. 381 funds tracked by Wall St. Rank hold CRSP as of Q1 2023.

Estabrook Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2023 after selling out during the quarter.
Estabrook Capital Management sold 12 CRISPR Therapeutics shares in Q1 2023, an estimated $488.
Estabrook Capital Management first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 13 quarters.
Estabrook Capital Management's CRISPR Therapeutics position peaked at $1.94K in Q2 2021.
381 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2023.

Based on Estabrook Capital Management's 13F filing for Q1 2023, filed 12 May 2023.